An update on locoregional percutaneous treatment technologies in colorectal cancer liver metastatic disease

References

• Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–1403.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:359–386.
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67:177–193.
   PubMed Web of Science ®Google Scholar
• Tsitskari M, Filippiadis D, Kostantos C, et al. The role of interventional oncology in the treatment of colorectal cancer liver metastases. Ann Gastroenterol. 2019;32:147–155.
   PubMed Web of Science ®Google Scholar
• Nieuwenhuizen S, Puijk RS, van den Bemd B, et al. Resectability and ablatability criteria for the treatment of liver only colorectal metastases: multidisciplinary consensus document from the COLLISION trial group. Cancers (Basel). 2020 Jul 3;12(7):1779.
   PubMed Web of Science ®Google Scholar
• Elferink MAG, Toes-Zoutendijk E, Vink GR, et al. Landelijkbevolkingsonderzoeknaarcolorectaalcarcinoom [National population screening for colorectal carcinoma in the Netherlands: results of the first years since the implementation in 2014]. Ned Tijdschr Geneeskd. 2018;162:D2283.
   PubMedGoogle Scholar
• Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002 Jun;235(6):759–766.
   PubMed Web of Science ®Google Scholar
• Poston G, Adam R, Vauthey JN. Downstaging or downsizing: time for a new staging system in advanced colorectal cancer? J Clin Oncol. 2006 Jun 20;24(18):2702–2706.
   PubMed Web of Science ®Google Scholar
• Clancy C, Burke JP, Barry M, et al. A meta-analysis to determine the effect of primary tumor resection for stage IV colorectal cancer with unresectable metastases on patient survival. Ann Surg Oncol. 2014 Nov;21(12):3900–3908.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–1422.
   PubMed Web of Science ®Google Scholar
• Wang DS, Louie JD, Sze DY. Intra-arterial therapies for metastatic colorectal cancer. Semin InterventRadiol. 2013;30:12–20.
   PubMed Web of Science ®Google Scholar
• Facciorusso A, Licinio R, Muscatiello N, et al. Transarterial chemoembolization: evidences from the literature and applications in hepatocellular carcinoma patients. World J Hepatol. 2015;7:2009–2019.
   PubMedGoogle Scholar
• Bala MM, Mituś JW, Riemsma RP, et al. Transarterial (chemo) embolisation versus chemotherapy for colorectal cancer liver metastases. Cochrane Database Syst Rev. 2017;8:CD012757.
   Google Scholar
• Raphael MJ, Karanicolas PJ. Regional therapy for colorectal cancer liver metastases: which modality and when? J Clin Oncol. 2022 Aug 20;40(24):2806–2817.
   PubMed Web of Science ®Google Scholar
• Scevola G, Loreni G, Rastelli M, et al. Third-line treatment of colorectal liver metastases using DEBIRI chemoembolization. Med Oncol. 2017;34:37.
   PubMed Web of Science ®Google Scholar
• Kow AWC. Hepatic metastasis from colorectal cancer. J Gastrointest Oncol. 2019 Dec;10(6):1274–1298.
   PubMed Web of Science ®Google Scholar
• Vogl TJ, Lahrsow M, Albrecht MH, et al. Survival of patients with non-resectable, chemotherapy-resistant colorectal cancer liver metastases undergoing conventional lipiodol-based transarterial chemoembolization (cTACE) palliatively versus neoadjuvantly prior to percutaneous thermal ablation. Eur J Radiol. 2018 May;102:138–145.
   PubMed Web of Science ®Google Scholar
• Albert M, Kiefer MV, Sun W, et al. Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. Cancer. 2011;117:343–352.
   PubMed Web of Science ®Google Scholar
• Vogl TJ, Lahrsow M. The role of conventional TACE (cTACE) and DEBIRI-TACE in colorectal cancer liver metastases. Cancers (Basel). 2022 Mar 15;14(6):1503.
   PubMed Web of Science ®Google Scholar
• Bhutiani N, Akinwande O, Martin RC. 2nd. efficacy and toxicity of hepatic intra-arterial drug-eluting (irinotecan) bead (DEBIRI) therapy in irinotecan-refractory unresectable colorectal liver metastases. World J Surg. 2016 May;40(5):1178–1190.
   PubMed Web of Science ®Google Scholar
• Aliberti C, Fiorentini G, Muzzio PC, et al. Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead®, drug-eluting bead loaded with irinotecan: results of a phase II clinical study. Anticancer Res. 2011;31::4581–4587.
   PubMed Web of Science ®Google Scholar
• Fiorentini G, Aliberti C, Tilli M, et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res. 2012;32:1387–1395.
   PubMed Web of Science ®Google Scholar
• Martin RCG, Scoggins CR, Schreeder M, et al. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer. 2015;121:3649–3658.
   PubMed Web of Science ®Google Scholar
• Akinwande O, Dendy M, Ludwig JM, et al. Hepatic intra- arterial injection of irinotecan drug eluting beads (DEBIRI) for patients with unresectable colorectal liver metastases: a systematic review. Surg Oncol. 2017;26:268–275.
   PubMed Web of Science ®Google Scholar
• Helmberger T, Lucatelli P, Pereira PL, et al. Safety, feasibility and technical considerations from a prospective, observational study-CIREL: irinotecan-TACE for CRLM in 152 patients. J Clin Med. 2022Oct19;11(20):6178.
   PubMed Web of Science ®Google Scholar
• Sofocleous CT, Violari EG, Sotirchos VS, et al. Radioembolization as a salvage therapy for heavily pretreated patients with colorectal cancer liver metastases: factors that affect outcomes. Clin Colorectal Cancer. 2015 Dec;14(4):296–305.
   PubMed Web of Science ®Google Scholar
• Sofocleous CT, Garcia AR, Pandit-Taskar N, Sofocleous CT, Garcia AR, Pandit-Taskar N, Do KG, Brody LA, Petre EN, Capanu M, Longing AP, Chou JF, Carrasquillo JA, Kemeny NE. Phase I trial of selective internal radiation therapy for chemorefractory colorectal cancer liver metastases progressing after hepatic arterial pump and systemic chemotherapy. Clin Colorectal Cancer. 2014 Mar;13(1):27–36.
   PubMed Web of Science ®Google Scholar
• Evans KA, Richardson MG, Pavlakis N, et al. Survival outcomes of a salvage patient population after radioembolization of hepatic metastases with yttrium-90 microspheres. J VascIntervRadiol. 2010;21:1521–1526.
   Google Scholar
• Hickey R, Lewandowski RJ, Prudhomme T, et al. 90Y radioembolization of colorectal hepatic metastases using glass microspheres: safety and survival outcomes from a 531-patient multicenter study. J Nucl Med. 2016;57:665–671.
   PubMed Web of Science ®Google Scholar
• Van Hazel GA, Heinemann V, Sharma NK, et al. SIRFLOX: randomized phase III trial Comparing first-line mFOLFOX6 (plus or minus Bevacizumab) versus mFOLFOX6 (plus or minus Bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol. 2016;34:1723–1731.
   PubMed Web of Science ®Google Scholar
• Wasan HS, Gibbs P, Sharma NK, et al. FOXFIRE-Global trial investigators. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol. 2017;18:1159–1171.
   PubMed Web of Science ®Google Scholar
• Manchec B, Kokabi N, Narayanan G, et al. Radioembolization of secondary hepatic malignancies. Semin InterventRadiol. 2021 Oct;38(4):445–452.
   PubMedGoogle Scholar
• Karanicolas P, Beecroft JR, Cosby R, et al., Regional therapies for colorectal liver metastases: systematic review and clinical practice guideline. gastrointestinal disease site group. Clin Colorectal Cancer. 2021;20(1): 20–28.
   PubMed Web of Science ®Google Scholar
• Rizzitelli S, Holtzman N, Maleux G, et al. Reduced nontarget embolization and increased targeted delivery with a reflux-control microcatheter in a swine model. Diagn Interv Imaging. 2021 Oct;102(10):641–648.
   PubMed Web of Science ®Google Scholar
• Rose SC, Halstead GD, Narsinh KH. Pressure-directed embolization of hepatic arteries in a porcine model using a temporary occlusion balloon microcatheter: proof of concept. Cardiovasc Intervent Radiol. 2017 Nov;40(11):1769–1776.
   PubMed Web of Science ®Google Scholar
• Lucatelli P, Rocco B, Ciaglia S, et al. Microballoon interventions for liver tumors: review of literature and future perspectives. J Clin Med. 2022Sep11;11(18):5334.
   PubMed Web of Science ®Google Scholar
• Ludwig JM, Iezzi R, Theysohn JM, et al. European multicenter study on degradable starch microsphere TACE. The digestible way to conquer HCC in patients with High tumor burden. Cancers 2021;13:20.
   Web of Science ®Google Scholar
• Schicho A, Pereira PL, Michalik K, et al. Safety and efficacy of transarterial chemoembolization with degradable starch microspheres (DSM-TACE) in the treatment of secondary liver malignancies. Onco Targets Ther. 2018;11:345–350.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Colon Cancer (Version 1.2020). Available online: http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf
   Google Scholar
• Filippiadis, Filippiadis DK, Velonakis G, et al. The role of percutaneous ablation in the management of colorectal cancer liver metastatic disease. Diagnostics (Basel). 2021;11(2):308.
   PubMedGoogle Scholar
• Cervantes A, Adam R, Roselló S, et al. ESMO guidelines committee. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†. Ann Oncol. 2022;S0923-7534(22):04192.
   Google Scholar
• Gillams A, Goldberg N, Ahmed M, et al. Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, the interventional oncology sans frontières meeting 2013. EurRadiol. 2015 Dec;25(12):3438–3454.
   Google Scholar
• Gillams AR, Lees WR. Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. EurRadiol. 2009 May;19(5):1206–1213.
   Google Scholar
• Mulier S, Ni Y, Jamart J, et al. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg. 2005 Aug;242(2):158–171.
   PubMed Web of Science ®Google Scholar
• Ayav A, Germain A, Marchal F, et al. Radiofrequency ablation of unresectable liver tumors: factors associated with incomplete ablation or local recurrence. Am J Surg. 2010 Oct;200(4):435–439.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Berber E. Role of thermal ablation in the management of colorectal liver metastasis.Hepatobiliary. SurgNutr. 2020;9(1):49–58.
   Google Scholar
• Petre EN, Sofocleous C. Thermal ablation in the management of colorectal cancer patients with oligometastatic liver disease. ViscMed. 2017 Mar;33(1):62–68.
   PubMed Web of Science ®Google Scholar
• Crocetti L, de Baére T, Pereira PL, et al. CIRSE standards of practice on thermal ablation of liver tumours. CardiovascInterventRadiol. 2020 Jul;43(7):951–962.
   Google Scholar
• Calandri M, Yamashita S, Gazzera C, et al. Ablation of colorectal liver metastasis: interaction of ablation margins and RAS mutation profiling on local tumour progression-free survival. EurRadiol. 2018 Jul;28(7):2727–2734.
   Google Scholar
• Benson AB, Venook AP, Al-Hawary MM, et al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl ComprCancNetw. 2021 Mar 2;19(3):329–359.
   Google Scholar
• Moulton CA, Gu CS, Law CH, et al. Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: a randomized clinical trial. JAMA. 2014 May 14;311(18):1863–1869.
   PubMed Web of Science ®Google Scholar
• Cornelis F, Sotirchos V, Violari E, et al. 18F-FDG PET/CT is an immediate imaging biomarker of treatment success after liver metastasis ablation. J Nucl Med. 2016 Jul. 57(7):1052–1057. Epub 2016 Feb 23. Erratum in: J Nucl Med. 2016 Aug;57(8):1325
   PubMed Web of Science ®Google Scholar
• Cornelis FH, Petre EN, Vakiani E, et al. Immediate postablation 18F-FDG injection and corresponding SUV are surrogate biomarkers of local tumor progression after thermal ablation of colorectal carcinoma liver metastases. J Nucl Med. 2018 Sep;59(9):1360–1365.
   PubMed Web of Science ®Google Scholar
• Sainani NI, Shyn PB, Tatli S, et al. PET/CT-guided radiofrequency and cryoablation: is tumor fluorine-18 fluorodeoxyglucose activity dissipated by thermal ablation? J VascIntervRadiol. 2011 Mar;22(3):354–360.
   Google Scholar
• Shady W, Petre EN, Gonen M, et al. Percutaneous radiofrequency ablation of colorectal cancer liver metastases: factors affecting outcomes–A 10-year experience at a single center. Radiology. 2016 Feb;278(2):601–611.
   PubMed Web of Science ®Google Scholar
• Bo XW, Xu HX, Guo LH, et al. Ablative safety margin depicted by fusion imaging with post-treatment contrast-enhanced ultrasound and pre-treatment CECT/CEMRI after radiofrequency ablation for liver cancers. Br J Radiol. 2017 Oct;90(1078):20170063.
   PubMed Web of Science ®Google Scholar
• Francica G, Meloni MF, Riccardi L, et al. Ablation treatment of primary and secondary liver tumors under contrast-enhanced ultrasound guidance in field practice of interventional ultrasound centers. A multicenter study Eur J Radiol. 2018;Aug 105 96–101.
   PubMed Web of Science ®Google Scholar
• Malone CD, Fetzer DT, Monsky WL, et al. Contrast-enhanced US for the interventional radiologist: current and emerging applications. Radiographics. 2020 Mar-Apr;40(2):562–588.
   PubMed Web of Science ®Google Scholar
• Solbiati L, Ierace T, Tonolini M, et al. Guidance and monitoring of radiofrequency liver tumor ablation with contrast-enhanced ultrasound. Eur J Radiol. 2004 Jun;51(Suppl):S19–23.
   PubMed Web of Science ®Google Scholar
• Mauri G, Gennaro N, De Beni S, et al. Real-time US-18FDG-PET/CT image fusion for guidance of thermal ablation of 18FDG-PET-positive liver metastases: the added value of contrast enhancement. Cardiovasc InterventRadiol. 2019 Jan;42(1):60–68.
   PubMed Web of Science ®Google Scholar
• Hoffmann RT. LebermetastasenkolorektalerKarzinome [Liver metastases of colorectal cancer]. Radiologe. 2017 Feb;57(2):90–96.
   PubMed Web of Science ®Google Scholar
• Hong K, Georgiades C. Radiofrequency ablation: mechanism of action and devices. J VascIntervRadiol. 2010 Aug;21(8 Suppl):S179–86.
   Google Scholar
• Filippiadis DK, Velonakis G, Kelekis A, et al. The role of percutaneous ablation in the management of colorectal cancer liver metastatic disease. Diagnostics (Basel). 2021 Feb 14;11(2):308.
   PubMedGoogle Scholar
• Fan H, Wang X, Qu J, et al. Periprocedural risk factors for incomplete radiofrequency ablation of liver metastases from colorectal cancer: a single-center retrospective analysis. Int J Hyperthermia. 2021;38(1):985–994.
   PubMed Web of Science ®Google Scholar
• Ierardi AM, Floridi C, Fontana F, et al. Microwave ablation of liver metastases to overcome the limitations of radiofrequency ablation. Radiol Med. 2013 Sep;118(6):949–961.
   PubMed Web of Science ®Google Scholar
• Izaaryene J, Drai M, Deniel C, et al. Computed tomography-guided microwave ablation of perivascular liver metastases from colorectal cancer: a study of the ablation zone, feasibility, and safety. Int J Hyperthermia. 2021;38(1):887–899.
   PubMed Web of Science ®Google Scholar
• van Tilborg AA, Scheffer HJ, de Jong MC, et al. MWA versus RFA for perivascular and peribiliary CRLM: a retrospective patient- and lesion-based analysis of two historical cohorts. Cardiovasc InterventRadiol. 2016 Oct;39(10):1438–1446.
   PubMed Web of Science ®Google Scholar
• Aghayev A, Tatli S. The use of cryoablation in treating liver tumors. Expert Rev Med Devices. 2014 Jan;11(1):41–52.
   PubMed Web of Science ®Google Scholar
• Erinjeri JP, Clark TW. Cryoablation: mechanism of action and devices. J VascIntervRadiol. 2010 Aug;21(8 Suppl):S187–91.
   Google Scholar
• Mala T. Cryoablation of liver tumours – a review of mechanisms, techniques and clinical outcome. Minim Invasive Ther Allied Technol. 2006;15(1):9–17.
   PubMed Web of Science ®Google Scholar
• Seifert JK, Junginger T. Cryotherapy for liver tumors: current status, perspectives, clinical results, and review of literature. Technol Cancer Res Treat. 2004 Apr;3(2):151–163.
   PubMed Web of Science ®Google Scholar
• Geboers B, Scheffer HJ, Graybill PM, et al. High-voltage electrical pulses in oncology: irreversible electroporation, electrochemotherapy, gene electrotransfer, electrofusion, and electroimmunotherapy. Radiology. 2020 May;295(2):254–272.
   PubMed Web of Science ®Google Scholar
• Lin YM, Paolucci I, Brock KK, et al. Image-guided ablation for colorectal liver metastasis: principles, current evidence, and the path forward. Cancers (Basel). 2021 Aug 4;13(16):3926.
   PubMed Web of Science ®Google Scholar
• Kim KR, Thomas S. Complications of image-guided thermal ablation of liver and kidney neoplasms. Semin Interv Radiol. 2014;31:138–148.
   PubMed Web of Science ®Google Scholar
• Laimer G, Schullian P, Bale R. Stereotactic thermal ablation of liver tumors: 3D planning, multiple needle approach, and intraprocedural image fusion are the key to success-a narrative review. Biology (Basel). 2021 Jul 10;10(7):644.
   PubMed Web of Science ®Google Scholar
• Kim H, Gill B, Beriwal S, et al. Cost-effectiveness analysis of stereotactic body radiation therapy compared with radiofrequency ablation for inoperable colorectal liver metastases. Int J Radiat Oncol Biol Phys. 2016;95:1175–1183.
   PubMed Web of Science ®Google Scholar
• Crocetti L. Radiofrequency ablation versus resection for small hepatocellular carcinoma: are randomized controlled trials still needed? Radiology. 2018;287:473–475.
   PubMed Web of Science ®Google Scholar
• Camacho JC, Petre EN, Sofocleous CT. Thermal ablation of metastatic colon cancer to the liver. Semin InterventRadiol. 2019 Oct;36(4):310–318.
   PubMed Web of Science ®Google Scholar
• Kamarinos NV, Dawson LA, Saltz LB, et al. Trials of locoregional therapies inspired by SABR-COMET. Lancet. 2020 Oct 3;396(10256):956–957.
   PubMed Web of Science ®Google Scholar
• Gavriilidis P, Roberts KJ, De’angelis N, et al. Recurrence and survival following microwave, radiofrequency ablation, and hepatic resection of colorectal liver metastases: a systematic review and network meta-analysis. Hepatobiliary Pancreat Dis Int. 2021 Aug;20(4):307–314.
   PubMed Web of Science ®Google Scholar
• Meijerink MR, Puijk RS, van Tilborg AAJM, et al. Radiofrequency and microwave ablation compared to systemic chemotherapy and to partial hepatectomy in the treatment of colorectal liver metastases: a systematic review and meta-analysis. Cardiovasc InterventRadiol. 2018 Aug;41(8):1189–1204.
   PubMed Web of Science ®Google Scholar
• Puijk RS, Ruarus AH, Lgph V, et al. Colorectal liver metastases: surgery versus thermal ablation (COLLISION) - a phase III single-blind prospective randomized controlled trial. BMC Cancer. 2018 Aug 15;18(1):821.
   PubMed Web of Science ®Google Scholar
• Pillai K, Al-Alem I, Akhter J, et al. Effect of nonparallel placement of in-circle bipolar radiofrequency ablation probes on volume of tissue ablated with heat sink. Surg Innov. 2015 Jun;22(3):223–234.
   PubMed Web of Science ®Google Scholar
• Rhaiem R, Kianmanesh R, Minon M, et al. Microwave thermoablation of colorectal liver metastases close to large hepatic vessels under Pringle maneuver minimizes the “heat sink effect.” World J Surg. 2020 May;44(5):1595–1603.
   PubMed Web of Science ®Google Scholar
• Yu NC, Raman SS, Kim YJ, et al. Microwave liver ablation: influence of hepatic vein size on heat-sink effect in a porcine model. J VascIntervRadiol. 2008 Jul;19(7):1087–1092.
   Google Scholar
• Silk MT, Wimmer T, Lee KS, et al. Percutaneous ablation of peribiliary tumors with irreversible electroporation. J VascIntervRadiol. 2014 Jan;25(1):112–118.
   Google Scholar
• Amabile C, Ahmed M, Solbiati L, et al. Microwave ablation of primary and secondary liver tumours: ex vivo, in vivo, and clinical characterisation. Int J Hyperthermia. 2017 Feb;33(1):34–42.
   PubMed Web of Science ®Google Scholar
• Simon CJ, Dupuy DE, Smith MWW. Microwave ablation: principles and applications. Radiographics. 2005;25:S69–S83.
   PubMed Web of Science ®Google Scholar
• Di Martino M, Rompianesi G, Mora-Guzmán I, et al. Systematic review and meta-analysis of local ablative therapies for resectable colorectal liver metastases. Eur J Surg Oncol. 2020 May;46(5):772–781.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Kahramangil B, Kose E, et al. A comparison of microwave thermosphere versus radiofrequency thermal ablation in the treatment of colorectal liver metastases. HPB (Oxford). 2018 Dec;20(12):1157–1162.
   PubMed Web of Science ®Google Scholar
• Filippiadis DK, Binkert C, Pellerin O, et al. CIRSE quality assurance document and standards for classification of complications: the CIRSE classification system. Cardiovasc Intervent Radiol. 2017;40:1141–1146.
   PubMed Web of Science ®Google Scholar
• Kurilova I, Bendet A, Petre EN, et al. Factors associated with local tumor control and complications after thermal ablation of colorectal cancer liver metastases: a 15-year retrospective cohort study. Clin Colorectal Cancer. 2021 Jun;20(2):e82–e95.
   PubMed Web of Science ®Google Scholar
• Patel IJ, Rahim S, Davidson JC, et al. Society of interventional radiology consensus guidelines for the periprocedural management of thrombotic and bleeding risk in patients undergoing percutaneous image-guided interventions-part ii: recommendations: endorsed by the Canadian Association for interventional radiology and the cardiovascular and interventional radiological society of Europe. J VascIntervRadiol. 2019 Aug;30(8):1168–1184.e1.
   Google Scholar
• Cassera MA, Potter KW, MB U, et al. Computed tomography (CT)-guided versus laparoscopic radiofrequency ablation: a single-institution comparison of morbidity rates and hospital costs. SurgEndosc. 2011 Apr;25(4):1088–1095.
   Google Scholar
• Cucchetti A, Piscaglia F, Cescon M, et al. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J Hepatol. 2013 Aug;59(2):300–307.
   PubMed Web of Science ®Google Scholar
• Minier C, Hermida M, Allimant C, et al. Software-based assessment of tumor margins after percutaneous thermal ablation of liver tumors: a systematic review. DiagnInterv Imaging. 2022 May;103(5):240–250.
   Google Scholar